Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Nutr Cancer 2005;53(2):177-93Immunotherapy and cancer vaccines in the management of breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-708Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-85Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-41Dendritic cell-based therapeutics for breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-01-01 / Breast Dis 2004;20:65-71The immune response to breast cancer, and the case for DC immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-01-01 / Cytotherapy 2004;6(2):154-63Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de